"To B(MP-2) or Not To B(MP-2)" or "Much Ado About Nothing": Are Orthobiologics in Tumor Surgery Worth the Risks?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25609065.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3069.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Geller and colleagues report that adjuvant chemotherapy affected the adequacy of osteosarcoma local surgical control. Exogenous bone morphogenetic protein-2 (BMP-2) did not increase local recurrence, but the limited theoretical benefits of BMP-2 for a subset of patients with osteosarcoma may not justify the systemic and long-term risks.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Bone Morphogenetic Protein 2
- Bone Neoplasms
- Neoplasm Recurrence, Local
- Osteosarcoma